Extended interval dosing with ocrelizumab in multiple sclerosis.
Novak F, Bajwa HM, Østergaard K, Berg JM, Madsen JS, Olsen DA, Urbonaviciute I, Illes Z, Stilund ML, Romme Christensen J, Bramow S, Sellebjerg F, Sejbaek T.
Novak F, et al. Among authors: bajwa hm.
Mult Scler. 2024 Apr 22:13524585241245296. doi: 10.1177/13524585241245296. Online ahead of print.
Mult Scler. 2024.
PMID: 38646949